ALK and lung adenocarcinoma: In our case, this ultra-aggressive phenotype, culminating in a fatal outcome within 12 days, stands in stark contrast to cases such as the anaplastic lymphoma kinase (ALK)-positive lung adenocarcinoma with PLR reported by Niu et al., where a patient survived for 5.2 months on lorlatinib [10].